AQST · Insider Trading
Aquestive Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by AQST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | John Cochran | Director | J | +62,229 | — |
| 2026-10-16 | Daniel Barber | President and CEO | Sell | −25,000 | −$105.60K |
| 2026-09-16 | Daniel Barber | President and CEO | Sell | −25,000 | −$120.49K |
| 2026-09-11 | Sherry Korczynski | Chief Commercial Officer | MIXED | — | −$22.49K |
| 2026-09-10 | Peter E. Boyd | Chief People Officer | X | +2,293 | +$2.20K |
| 2026-09-09 | Daniel Barber | President and CEO | X | +91,743 | +$88.07K |
| 2026-09-08 | Cassie Jung | Chief Operating Officer | X | +4,587 | +$4.40K |
| 2026-08-18 | Daniel Barber | President and CEO | Sell | −25,000 | −$107.17K |
| 2026-08-17 | Sherry Korczynski | Chief Commercial Officer | F | −2,714 | −$11.53K |
| 2026-07-17 | Daniel Barber | President and CEO | Sell | −25,000 | −$100.19K |
| 2026-06-24 | Julie Krop | Director | MIXED | — | −$107.56K |
| 2026-06-16 | Daniel Barber | President and CEO | Sell | −25,000 | −$104.01K |
| 2026-06-12 | Marco Taglietti | Director | A | +50,500 deriv. | — |
| 2026-06-12 | Abigail L. Jenkins | Director | A | −50,500 deriv. | — |
| 2026-06-12 | Julie Krop | Director | A | +50,500 deriv. | — |
| 2026-06-12 | Timothy E Morris | Director | A | +50,500 deriv. | — |
| 2026-06-12 | John Cochran | Director | A | — | — |
| 2026-06-12 | Gregory B Brown | Director | A | — | — |
| 2026-06-09 | Sherry Korczynski | Chief Commercial Officer | F | −2,714 | — |
| 2026-05-19 | Thomas A. Zalewski | Chief Legal Officer | A | +100,000 | — |
| 2026-05-18 | Melina Cioffi | SVP, Regulatory Affairs | F | −1,667 | −$6.95K |
| 2026-05-18 | Daniel Barber | President and CEO | Sell | −8,257 | −$35.41K |
| 2026-05-11 | Lori J Braender | Corporate Secretary | F | −135,690 | −$573.97K |
| 2026-05-07 | Daniel Barber | President and CEO | F | −335,922 | −$1.40M |
| 2026-05-07 | Lori J Braender | Corporate Secretary | F | −76,147 | −$318.29K |
| 2026-05-07 | Cassie Jung | Chief Operating Officer | F | −72,734 | −$304.03K |
| 2026-05-07 | A Ernest Toth Jr | Chief Financial Officer | F | −92,652 | −$387.29K |
| 2026-05-07 | Peter E. Boyd | Chief People Officer | F | −56,778 | −$237.33K |
| 2026-04-13 | Sherry Korczynski | Chief Commercial Officer | A | +67,500 deriv. | — |
| 2026-04-13 | Cassie Jung | Chief Operating Officer | A | +60,000 deriv. | — |
| 2026-04-13 | Lori J Braender | Corporate Secretary | A | +82,500 deriv. | — |
| 2026-04-13 | Daniel Barber | President and CEO | A | +293,100 deriv. | — |
| 2026-04-13 | A Ernest Toth Jr | SVP, Chief Financial Officer | A | +82,500 deriv. | — |
| 2026-04-13 | Peter E. Boyd | Chief People Officer | A | +60,000 deriv. | — |
| 2026-03-11 | Melina Cioffi | SVP, Regulatory Affairs | MIXED | +74,689 | −$105.62K |
| 2026-03-11 | Matthew W. Davis | Chief Development Officer | A | +50,000 | — |
| 2026-03-11 | Peter E. Boyd | Chief People Officer | MIXED | +50,186 | −$124.41K |
| 2026-03-11 | Lori J Braender | Chief Legal Officer | MIXED | +39,898 | −$167.35K |
| 2026-03-11 | Cassie Jung | Chief Operating Officer | MIXED | +34,209 | −$191.09K |
| 2026-03-11 | A Ernest Toth Jr | Chief Financial Officer | MIXED | +36,746 | −$243.09K |
| 2026-03-11 | Daniel Barber | President and CEO | MIXED | +81,323 | −$753.97K |
| 2026-03-11 | Sherry Korczynski | Chief Commercial Officer | MIXED | +59,259 | −$65.69K |
| 2026-03-11 | Matthew J. Greenhawt | Chief Medical Officer | A | +75,000 | — |
| 2025-12-05 | Peter E. Boyd | Chief People Officer | A | +20,000 | — |
| 2025-12-04 | Melina Cioffi | SVP, Regulatory Affairs | F | −2,083 | −$12.35K |
| 2025-11-12 | Matthew W. Davis | Chief Development Officer | A | +50,000 | — |
| 2025-10-17 | Carl N Kraus | Chief Medical Officer | Sell | −20,272 | −$141.90K |
| 2025-10-17 | Cassie Jung | Chief Operating Officer | MIXED | −42,575 | −$396.13K |
| 2025-10-17 | Peter E. Boyd | See Remarks | Sell | −10,000 | −$70.00K |
| 2025-09-29 | Peter E. Boyd | See Remarks | Sell | −10,000 | −$63.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel Barber | President and CEO | 627,317 | $2.49M |
| Stephen Wargacki | Chief Science Officer | 363,555 | $1.44M |
| Peter E. Boyd | Chief People Officer | 284,024 | $1.13M |
| A Ernest Toth Jr | Chief Financial Officer | 283,460 | $1.13M |
| Carl N Kraus | Chief Medical Officer | 282,475 | $1.12M |
| Melina Cioffi | SVP, Regulatory Affairs | 273,200 | $1.08M |
| Sherry Korczynski | Chief Commercial Officer | 244,439 | $970.42K |
| Lori J Braender | Corporate Secretary | 231,042 | $917.24K |
| Cassie Jung | Chief Operating Officer | 208,833 | $829.07K |
| John Cochran | Director | 161,715 | $642.01K |
| Matthew W. Davis | Chief Development Officer | 100,000 | $397.00K |
| Thomas A. Zalewski | Chief Legal Officer | 100,000 | $397.00K |
| Matthew J. Greenhawt | Chief Medical Officer | 77,000 | $305.69K |
| Gregory B Brown | Director | 75,085 | $298.09K |
| Douglas K Bratton | Director | 59,636 | $236.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AQST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.